NCT05095207 2026-04-13
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT06222593 2026-04-01
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
State University of New York at Buffalo
Phase 1/2 Recruiting
NCT03090165 2026-01-02
Ribociclib and Bicalutamide in AR+ TNBC
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT02605486 2025-07-03
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT00924807 2018-12-11
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
Phase 1/2 Terminated
NCT00878436 2018-02-07
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
NYU Langone Health
Phase 1/2 Completed
NCT01020305 2014-10-13
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Stanford University
Phase 1/2 Terminated
NCT00075192 2012-06-06
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
AstraZeneca
Phase 1/2 Completed